74 results
S-3ASR
EX-4.3
NRIX
Nurix Therapeutics Inc
11 Jun 24
Automatic shelf registration
4:06pm
, but the Company may require payment of a sum sufficient to cover any tax or other governmental charge payable in connection therewith.]
[Prior to due
S-3ASR
NRIX
Nurix Therapeutics Inc
11 Jun 24
Automatic shelf registration
4:06pm
securities or debt securities in bearer form, we will describe material U.S. federal income tax considerations and other material special considerations … currency or currencies or a foreign currency unit or units. If we do, we will describe the restrictions, elections, and general tax considerations relating
S-3ASR
EX-4.4
NRIX
Nurix Therapeutics Inc
11 Jun 24
Automatic shelf registration
4:06pm
in writing.
Any exchange or transfer shall be without charge, except that the Company may require payment by the Holder of a sum sufficient to cover any tax … in any applicable Federal income tax law with the effect that, and such opinion shall confirm that, the Holders of the outstanding Securities
8-K
EX-1.1
NRIX
Nurix Therapeutics Inc
12 Apr 24
Nurix Therapeutics Announces Pricing of Upsized $175.0 Million Public Offering
5:12pm
legal, tax, investment, accounting or regulatory matters in any jurisdiction. The Company shall consult with its own advisors concerning such matters … of the Commission thereunder.
(x) Taxes. The Company and its subsidiaries have paid all federal, state, local and foreign taxes and filed all tax returns
8-K
EX-4.1
NRIX
Nurix Therapeutics Inc
12 Apr 24
Nurix Therapeutics Announces Pricing of Upsized $175.0 Million Public Offering
5:12pm
of this Warrant shall be made without charge to the Holder for any issue or transfer tax, transfer agent fee or other incidental tax or expense (excluding any … , however, that the Company shall not be required to pay any tax that may be payable in respect of any transfer involved in the registration of any
424B5
2484gbihyznnp742
12 Apr 24
Prospectus supplement for primary offering
5:10pm
424B5
c8lr2
11 Apr 24
Prospectus supplement for primary offering
4:06pm
8-K
EX-99.1
cmp27522r303m
6 Oct 22
Nurix Therapeutics Reports Third Quarter Fiscal 2022 Financial Results and Provides a Corporate Update
4:10pm
8-K
EX-4.1
4xjdi gknffxn5
8 Jul 22
Nurix Therapeutics Announces $55 Million Registered Direct Offering
4:13pm
8-K
EX-10.1
93fvu
8 Jul 22
Nurix Therapeutics Announces $55 Million Registered Direct Offering
4:13pm